Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF 5993 versus Ultibro in COPD exacerbation prevention
2014-001704-22Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing CHF 5993 pMDI arm with Ultibro DPI arm (2 arms). Primary endpoint: Moderate and severe COPD exacerbation rate over 52 weeks of treatment. Started Dec 2014; status: completed.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrroniumindacaterol + glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2014-001704-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001704-22.